ArticleThe New England journal of medicine2018
Pembrolizumab plus Chemotherapy in Lung Cancer.
Article in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Molecular cancer research : MCR · 2021Trial
- Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study.Advances in therapy · 2026Article
- Safety and Efficacy of Bronchoscopic Pulsed Electric Field Ablation for Lung Cancer and Metastases.JTO clinical and research reports · 2026Article
- Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.Translational lung cancer research · 2026Article
- COPD is associated with poorer survival in patients with advanced non-small cell lung cancer treated with first-line ICI plus chemotherapy.BMC pulmonary medicine · 2026Article
- Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings.JTO clinical and research reports · 2026Article
- Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025Review
- Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.JTO clinical and research reports · 2024Article
- Modulating Tumor Immunity by Targeting Tumor Fibrotic Stroma and Angiogenic Vessels for Lung Cancer Treatment.Cancers · 2024Article
- CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.Cell reports. Medicine · 2024Article
- Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.Cancer medicine · 2024Article
- Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer.Future oncology (London, England) · 2024Article
- Malignant pleural disease.Breathe (Sheffield, England) · 2023Review
- Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.Genes & diseases · 2023Review
- Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects.JTO clinical and research reports · 2023Article
- Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response.Seminars in cancer biology · 2022Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30207917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.